Allovir
2013
FOUNDED
PRIVATE
STATUS
Series B
LATEST DEAL TYPE
$121M
LATEST DEAL AMOUNT
13
INVESTORS
Description
Developer of thymocytes cell therapies designed to treat viral infections. The company's thymocytes cell therapies eliminates deadly viral infections in immune compromised patients by using virus killing thymocytes cells and offers a personalized product prepared from the HSCT donor that can be used to prevent viral infections, enabling doctors to treat viral infections and helps patients to recover the same.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 2925 Richmond Avenue
- Suite 1200, Kirby Grove
- Houston, TX 77098
- United States
+1 (936) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Allovir’s full profile, request a free trial.
Allovir Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC (Series B) | 21-May-2019 | $121M | 00000 | 00000 | Completed | Clinical Trials - Phase 2 |
| 7. Later Stage VC | 18-Dec-2018 | 00.00 | 000.00 | 00000 | Completed | Generating Revenue |
| 6. Early Stage VC | 02-Oct-2018 | 0000 | 0000 | Completed | Clinical Trials - Phase 2 | |
| 5. Grant | 21-Aug-2017 | 00.000 | Completed | Startup | ||
| 4. Grant | 05-Jul-2017 | 00.000 | Completed | Startup | ||
| 3. Grant | 01-Jan-2017 | 00000 | Completed | Startup | ||
| 2. Accelerator/Incubator | 02-Mar-2016 | Completed | Startup | |||
| 1. Angel (individual) | 01-Jan-2014 | Completed | Startup |
Allovir Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A4 | 0,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.00 |
| Series A3 | 00,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Series A2 | 20,000,000 | $0.000100 | 8% | $1.5 | $1.5 | 1x | $1.5 | 22.29% |
| Series A1 | 20,000,000 | $0.000100 | 8% | $1.5 | $1.5 | 1x | $1.5 | 22.29% |
Allovir Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| EcoR1 Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | ||
| F2 Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Fidelity Management & Research | Asset Manager | Minority | 000 0000 | 000000 0 | ||
| Gilead Sciences | Corporation | Minority | 000 0000 | 000000 0 | ||
| Redmile Group | Hedge Fund | Minority | 000 0000 | 000000 0 |
Allovir Executive Team (9)
1 Former Executive
You’re viewing 5 of 9 executives. Get the full list »Allovir Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Ansbert Gadicke | Allovir | Board Member | 000 0000 | |
| David Hallal | Allovir | Chief Executive Officer & Chairman | 000 0000 | |
| John Wilson | Allovir | Board Member | 000 0000 | |
| Juan Vera MD | Allovir | Co-Founder, Chief Product Development Officer & Board Member | 000 0000 | |
| Malcolm Brenner MD | Allovir | Advisor & Board Member | 000 0000 |